Bertrand Tombal

Nov 15, 2024 | urotoday.com | Bertrand Tombal

Read the Full Video TranscriptBertrand Tombal: Thank you. So the question here is a little bit different. We are speaking mostly about EMBARK patients, which are very late patients. And the question, as I understood, is that now that you have an EMBARK patient, is there still a role for local salvage treatment? These are my conflicts of interest. As usual, I'm going to try to get a very provocative approach, at least for the sake of the discussion. So this is basically what we do.

Sep 23, 2024 | urotoday.com | Bertrand Tombal

Read the Full Video TranscriptOliver Sartor: Hi. I'm Dr. Oliver Sartor with UroToday, and it's really a pleasure and honor for me to have Bertrand Tombal join us to be able to discuss the PEACE-3 data that was presented at ESMO 2024 in Barcelona. Bertrand is incredibly well-known to our listeners, former president of the EORTC and all-round leader in terms of prostate cancer research. Welcome, Bertrand. Bertrand Tombal: My pleasure being with you. Thank you for inviting me.

Apr 23, 2024 | urotoday.com | Bertrand Tombal

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Bertrand Tombal, who is joining me from Brussels, Belgium. Thank you so much for being here with me today. Bertrand Tombal: My pleasure as always. Alicia Morgans: Wonderful. Bertrand, I just wanted to give you the opportunity to present some data that you spoke about at EAU 2024, giving us an understanding of the European population within the ARASENS data set.

Apr 22, 2024 | europeanurology.com | Fred Saad |E. David Crawford |Luke T Nordquist |Maha Hussain |Bertrand Tombal |Karim Fizazi | +10 more

AbstractAddition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and their association with outcomes. ARASENS is an international, double-blind, phase 3 study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to darolutamide 600 mg orally twice daily (n = 651) or placebo (n = 654), both with ADT + docetaxel.

Apr 4, 2023 | onclive.com | Bertrand Tombal |Cliniques Universitaires Saint-Luc

Bertrand Tombal, MD, PhD, professor of Physiology, chair of the Division of Urology, the Université catholique de Louvain, the Cliniques universitaires Saint-Luc, in Brussels, Belgium, discusses the pharmacokinetics of darolutamide (Nubeqa) plus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).